Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 21/Aug 19:36
Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies | Medivir, 4SC
Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Assessment According to DelveInsight’s evaluation, globally, more than 25 key pharmaceutical and biotechnology companies are actively developing over 27 pipeline drugs within
Articles similaires
Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics
mountaintoday.in - 04/Sep 07:57
Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
zacks.com - 14:47
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
A More Efficient FDA Approval Process: An Expert’s Proposal
theparadise.ng - 06/Sep 00:50
The Food and Drug Administration (FDA), as many are aware, is the leading entity for the regulation and safety testing for foods and pharmaceuticals...
Research spotlight: Key regulators of pd-1 in melanoma cells and the immune system’s response
oncologynews.com.au - 30/Aug 13:57
Immune checkpoint inhibitors are cancer-fighting drugs that help the immune system do its job of detecting and attacking tumour cells. Programmed Cell...
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
stockhead.com.au - 02/Sep 01:28
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
stockhead.com.au - 02/Sep 01:28
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
Les derniers communiqués
-
Aucun élément